Association between TM6SF2 rs58542926 T/C gene polymorphism and significant liver fibrosis: A meta-analysis

Abstract Background Hepatocellular carcinoma (HCC) is the sixth-most common malignancy worldwide. Multiple previous studies have assessed the relationship between TM6SF2 gene polymorphism and the risk of developing HCC, with discrepant conclusions reached. To assess the association of TM6SF2 rs58542926 T/C gene polymorphism with liver cancer, we performed the current meta-analysis. Methods This study queried the MEDLINE, PubMed, EMBASE, and CENTRAL databases from inception to April 2019. Case-control studies assessing the relationship between TM6SF2 rs5854292 locus polymorphism and liver cancer were selected according to inclusion and exclusion criteria. The Stata 12.0 software was employed for data analysis. Results A total of 5 articles, encompassing 6873 patients, met inclusion criteria and were included in the meta-analysis. Statistical analysis showed that the TM6SF2 gene polymorphism was significantly associated with liver cancer in the allele contrast, dominant, recessive and over dominant models (T vs C, OR = 1.621, 95%CI 1.379–1.905; CT + TT vs CC. OR = 1.541, 95%CI 1.351–1.758; TT vs CT + CC, OR = 2.897, 95%CI 1.690–4.966; CC + TT vs TC, OR = 0.693, 95%CI 0.576–0.834). The Egger’s test revealed no significant publication bias. Conclusion The present findings suggest a significant association of TM6SF2 gene polymorphism with HCC risk in the entire population studied.

Download Full-text

Association of ABO Polymorphisms and Pancreatic Cancer/ Cardiocerebrovascular Disease: a Meta-analysis.

10.21203/rs.2.23107/v3 ◽

2020 ◽

Author(s):

Yanxia Li ◽

Luyang Liu ◽

Yubei Huang ◽

Hong Zheng ◽

Lian Li

Keyword(s):

Web Of Science ◽

Meta Analysis ◽

Case Control ◽

Case Control Studies ◽

Exclusion Criteria ◽

Bias Assessment ◽

Heterogeneity Test ◽

Pancreatic Cancers ◽

The Relationship ◽

Eligible Case

Abstract Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

Download Full-text

Association between the Interleukin-10 -1082 G/A polymorphism and risk of hepatocellular carcinoma

African Health Sciences ◽

10.4314/ahs.v20i1.40 ◽

2020 ◽

Vol 20 (1) ◽

pp. 351-358

Author(s):

Yingwei Wang ◽

Peiyang Hu

Keyword(s):

Hepatocellular Carcinoma ◽

Meta Analysis ◽

Group Analysis ◽

Interleukin 10 ◽

Recessive Model ◽

Case Control Studies ◽

Exclusion Criteria ◽

Keywords Hepatocellular Carcinoma ◽

Relationship Of ◽

The Relationship

Background: Inconsistent results have been reported from studies investigating the relationship of the interleukin-10 (IL-10) -1082 G/A polymorphism and the susceptibility of hepatocellular carcinoma (HCC). Therefore, a thorough literature review of relatedstudies was performed in this meta-analysis to examine the association of the interleukin-10(IL-10) -1082 G/A poly- morphism with HCC susceptibility. Methods: Electronic databases were searched for literature on the relationship between interleukin-10(IL-10) -1082 G/A poly- morphism and the risk of HCC in accordance with the inclusion and exclusion criteria. The selected studies were analyzed using the Stata 12.0 software. Finally, the strength of the associations was evaluated using the odds ratio (OR) and 95% confidence intervals (95% CI). Results: A total of six case-control studies were enrolled into the current meta-analysis, which included a total of 911 patients and 1889 control subjects. Our data revealed no association between the IL-10 -1082 G/A polymorphism and the risk of HCC (GG vs AA:OR=0.84, 95%CI=0.57-1.25; AG vs AA:OR=0.85, 95%CI=0.70-1.05; Dominant model: OR=0.85, 95%CI=0.70- 1.03; and Recessive model: OR=0.92, 95%CI = 0.64-1.32). Similarly, no association was found in sub-group analysis based on ethnicity. Conclusion: The results of our study suggest no association between IL-10 -1082 G/A polymorphism and the risk of HCC. Keywords: Hepatocellular carcinoma; IL-10 polymorphism; risk analysis.

Download Full-text

Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis

The International Journal of Biological Markers ◽

10.1177/1724600818792897 ◽

2018 ◽

Vol 33 (4) ◽

pp. 364-371 ◽

Cited By ~ 4

Author(s):

Fei Lv ◽

Yanju Ma ◽

Ye Zhang ◽

Zhi Li

Keyword(s):

Gene Polymorphism ◽

Odds Ratio ◽

Adverse Reactions ◽

Genetic Model ◽

Meta Analysis ◽

Case Control ◽

Case Control Studies ◽

Dominant Genetic Model ◽

Positive Report ◽

The Relationship

Although many previous studies have reported the relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs, the conclusions are not consistent. The aim of the study is to evaluate the association between granulocytopenia and thrombocytopenia induced by platinum-based drugs and GSTP1 rs1695 gene polymorphism by meta-analysis. A literature search was performed using the Pubmed, Embase, CNKI, and Wanfang databases, and the odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the correlation. Finally,12 case-control studies comprising 1657 patients were included in our study. GSTP1 rs1695 gene polymorphism showed a significant correlation with granulocytopenia induced by platinum-based drugs (dominant genetic model: OR=1.60, 95% CI=1.19. 2.15, P=0.002; recessive genetic model: OR=3.72, 95% CI=1.73, 8.00, P=0.001; allelic genetic model: OR=1.76, 95% CI=1.34, 2.33, P=0.001). This gene polymorphism is not associated with thrombocytopenia (OR=0.87, 95% CI=0.47, 1.60, P=0.649). False-positive report probability showed that the association between polymorphism and adverse reactions is true. Sensitivity analysis showed that the results were stable. However, there was a certain publication bias in the included studies. In conclusion, the GSTP1 rs1695 gene polymorphism is associated with granulocytopenia induced by platinum-based drugs.

Download Full-text

Association of ABO Polymorphisms and Cancer/Cardiocerebrovascular Disease: a Meta-analysis

10.21203/rs.2.14412/v1 ◽

2019 ◽

Author(s):

Yanxia Li ◽

Luyang Liu ◽

Yubei Huang ◽

Hong Zheng ◽

Lian Li

Keyword(s):

Gene Polymorphisms ◽

Web Of Science ◽

Meta Analysis ◽

Case Control ◽

Case Control Studies ◽

Exclusion Criteria ◽

Bias Assessment ◽

Heterogeneity Test ◽

The Relationship ◽

Eligible Case

Abstract Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular diseases. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/cardiocerebrovascular diseases. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results: A total of eighteen articles involving twenty-nine case-control populations were included according to inclusion and exclusion criteria. Eleven populations (16,929 cases and 23,941 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95% CI=1.04-1.22, P=0.003), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P<0.001). Four populations (5,158 cases and 7,021 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.16, 95%CI=1.09-1.24, P<0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P<0.001). Conclusion: Our study suggested that ABO polymorphisms may serve as a risk factor of cancers and cardiocerebrovascular diseases.

Download Full-text

Association between dopamine receptor D2 genetic polymorphism TaqIA1 (C t) and susceptibility to alcohol dependence

10.1101/2020.04.15.20066498 ◽

2020 ◽

Author(s):

Amrita Choudhary ◽

Upendra Yadav ◽

Pradeep Kumar ◽

Vandana Rai

Keyword(s):

Alcohol Dependence ◽

Dopamine Receptor ◽

Meta Analysis ◽

Asian Population ◽

Recessive Model ◽

Case Control Studies ◽

Drd2 Gene ◽

Contrast Model ◽

The Relationship ◽

Allele Contrast

AbstractSeveral studies are published, which investigated dopamine receptor 2 (DRD2) gene TaqIA polymorphism as ris factor for alcohol dependence (AD) with positive and negative association. To derive a more precise estimation of the relationship, a meta-analysis of case-control studies that examined the association between DRD2 gene Taq1A polymorphism and alcohol dependence were performed. Eligible articles were identified through search of databases including PubMed, Science Direct, Springer link and Google Scholar. The association between the DRD2 TaqIA polymorphism and AD susceptibility was conducted using odds ratios (ORs) and 95 % confidence intervals (95 % CIs) as association measure.A total of 69 studies with 9,125 cases and 9,123 healthy controls were included in current meta-analysis. Results of present analysis showed significant association between DRD2 TaqIA polymorphism and AD risk using a five genetic modes (allele contrast model -OR=1.22, 95% CI=1.13-1.32, p<0.0001; homozygote model -OR= 1.35, 95%CI= 1.18-1.55; p= <0.0001; dominant model -OR= 1.29; 95%CI= 1.20-1.39; p<0.0001; recessive model-OR= 1.21; 95%CI= 1.08-1.36; p= 0.0006). There was no significant association found between In subgroup analysis, TaqIA polymorphism was not significantly associated with AD risk in Asian population under all genetic models, but in Caucasian population TaqIA polymorphism was significantly associated with AD risk.Overall, results support the hypothesis that DRD2 Taq1A polymorphism plays a role in alcohol dependence.

Download Full-text

Association of ABO Polymorphisms and Pancreatic Cancer/ Cardiocerebrovascular Disease: a Meta-analysis.

10.21203/rs.2.23107/v2 ◽

2020 ◽

Author(s):

Yanxia Li ◽

Luyang Liu ◽

Yubei Huang ◽

Hong Zheng ◽

Lian Li

Keyword(s):

Web Of Science ◽

Meta Analysis ◽

Case Control ◽

Case Control Studies ◽

Exclusion Criteria ◽

Bias Assessment ◽

Heterogeneity Test ◽

Pancreatic Cancers ◽

The Relationship ◽

Eligible Case

Abstract Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

Download Full-text

Association of ABO Polymorphisms and Pancreatic Cancer/Cardiocerebrovascular Disease: a Meta-analysis

10.21203/rs.2.23107/v1 ◽

2020 ◽

Author(s):

Yanxia Li ◽

Luyang Liu ◽

Yubei Huang ◽

Hong Zheng ◽

Lian Li

Keyword(s):

Web Of Science ◽

Meta Analysis ◽

Case Control ◽

Case Control Studies ◽

Exclusion Criteria ◽

Bias Assessment ◽

Heterogeneity Test ◽

Pancreatic Cancers ◽

The Relationship ◽

Eligible Case

Abstract Background: ABO gene polymorphisms have been reported to be associated with the risk of multiple cancers and cardiocerebrovascular disease s. However, the results remained controversial. In this study, we conducted a systematic review and meta-analysis to clarify the association between two SNPs (rs505922 and rs657152) in ABO gene and cancers/ cardiocerebrovascular disease s. Method: All eligible case-control studies come from PubMed, Embase and Web of Science up to Jan. 1, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results : A total of nineteen articles involving twenty-two case-control populations were included according to inclusion and exclusion criteria. Twelve populations (20,820 cases and 27,837 controls) were used to evaluate the relationship between rs505922 and overall cancers and nine populations (22,275 cases and 71,549 controls) were included to assess the association between rs505922 and cardiocerebrovascular diseases. The results showed a significant association between the rs505922 polymorphism and cancers (CvsT: OR=1.13, 95%CI=1.05-1.22, P =0.001), and cardiocerebrovascular diseases (OR=1.36, 95%CI=1.19-1.57, P <0.001). Five populations (8,660 cases and 10,618 controls) were included to evaluate association between rs657152 and cancers and five populations (8,105 cases and 6,712 controls) were included to estimate the relationship between rs657152 and cardiocerebrovascular diseases. The result of meta-analysis reveals that rs657152 was significantly associated with cancers (OR=1.18, 95%CI=1.13-1.23, P <0.001) and cardiocerebrovascular diseases (OR=1.54, 95%CI=1.24-1.92, P <0.001). Conclusion: Our study suggested that ABO polymorphisms might serve as a risk factor of pancreatic cancers and cardiocerebrovascular diseases.

Download Full-text

Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis

10.1101/2020.05.19.20106385 ◽

2020 ◽

Author(s):

Shan Tang ◽

Jing Zhang ◽

Tingting Mei ◽

Haiqing Guo ◽

Xinhuan Wei ◽

...

Keyword(s):

Liver Disease ◽

Gene Polymorphism ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Meta Analysis ◽

Case Control ◽

Case Control Studies ◽

Alcoholic Fatty Liver ◽

Nonalcoholic Fatty Liver ◽

The Relationship

Objective:To systematically review the association of PNPLA3 rs738409 G/C gene polymorphism with non-alcoholic fatty liver disease(NAFLD) in children. Design: Systematic review and meta-analysis. Data sources and study selection: We searched MEDLINE, PubMed, EMBASE, and CENTRAL databases from inception to May 2019. Case-control studies assessing the relationship between PNPLA3 rs738409 G/C gene polymorphism with non-alcoholic fatty liver disease in children were selected according to inclusion and exclusion criteria. Data extraction and analyses: First author's surname, publication year, country, total numbers of patients in the case and control groups, sex ratio, and body mass index (BMI), as well as the numbers of cases and controls with the C/C, C/G and G/G genotypes were extracted from the included studies. Random effects model was used to quantify the association between the PNPLA3 rs738409 G/C gene polymorphism and the susceptibility of children's NAFLD. Fixed effects model was used to quantify the relationship between the PNPLA3 rs738409 G/C gene polymorphism and the severity of NAFLD in children. Results: A total of nine case-control studies were included in this meta-analysis containing data of 1173 children with NAFLD and 1792 healthy controls. Five studies compared NAFLD children and non-NAFLD healthy populations. Statistical analysis showed that PNPLA3 gene polymorphism was significantly associated with children's NAFLD in the allele contrast, dominant, recessive and over dominant models (G vs C,OR=3.343, 95% CI=1.524-7.334; GG+GC vs CC,OR=3.157, 95% CI=1.446-6.892;GG vs GC+CC,OR=5.692, 95% CI=1.941-16.689; GG+CC vs GC,OR=2.756, 95% CI=1.729-4.392). Four case-control studies compared Children with nonalcoholic fatty liver(NAFL) and children with nonalcoholic steatohepatitis(NASH). The results showed that the PNPLA3 gene polymorphism was also significantly associated with the severity of NAFLD in children in recessive gene model(GG vs GC+CC,OR = 14.43, 95% CI = 5.985-34.997); The Egger's test revealed no significant publication bias. Conclusions: Meta-analysis showed that PNPLA3 gene polymorphism was significantly associated with susceptibility and severity of NAFLD in children. trial registration number： CRD42019134056.

Download Full-text

The M235T polymorphism in the angiotensinogen gene is not a major risk factor for diabetic nephropathy; a meta-analysis

Journal of Preventive Epidemiology ◽

10.34172/jpe.2022.15 ◽

2021 ◽

Vol 7 (1) ◽

pp. e15-e15

Author(s):

Bhuneshwar Sahu ◽

Shashikant Swarnakar ◽

Henu Kumar Verma ◽

Thavanati Parvathi Kumara Reddy ◽

Smaranika Pattnaik ◽

...

Keyword(s):

Diabetic Nephropathy ◽

Gene Polymorphism ◽

Meta Analysis ◽

Large Population ◽

Population Based ◽

Case Control Studies ◽

Stratified Analysis ◽

High Degree ◽

The Relationship ◽

M235t Polymorphism

Introduction: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease in diabetes patients. The angiotensin AGT M235T gene polymorphism, which is linked to the renin-angiotensin-aldosterone system (RAAS), has been extensively studied in DN patients, but the results are still conflicting. The current study’s goal is to conduct a meta-analysis to assess the relationship between AGT M235T gene polymorphism and DN susceptibility. Methods: Fourteen case-control studies related to AGT M235T polymorphism and DN were searched using PubMed, Web of Science and Google Scholar databases. Genotype data from the T2DM and T2DN groups were collected from all papers. The pooled odds ratio (OR) and 95 percent confidence interval (95% CI) were calculated employing a random-effects model to assess the relationship. Results: There were no statistically significant link between AGT M235T and DN risk in dominant (P=0.801, OR: 0.95; 95% CI: 0.66-1.38), allelic (P=0.933, OR: 1.01; 95% CI: 0.75-1.37) and recessive (P=0.374, OR: 1.21; 95% CI: 0.80-1.83) genetic models. Further, the stratified analysis based on ethnicity did not reveal significant link between AGT M235T and DN risk in Asian (Dom OR: 1.07; 95% CI: 0.63-1.82) and the Caucasian populations (Dom OR: 0.77; 95% CI: 0.49-1.21). In all three models, there was a high degree of heterogeneity between studies. Publication bias was not seen. Conclusion: Our findings suggest that the AGT gene M235T polymorphism does not contribute to DN risk. However, validation of this association will require multi-center and large population-based studies.

Download Full-text